24 July 2013Americas

USPTO announces departure of general counsel

The chief legal officer at the United States Patent and Trademark Office (USPTO) has announced he will be leaving.

Bernard Knight will be leaving in August after holding the position of general counsel for four years.

During his time in the post he oversaw the adoption of new rules required to implement the America Invents Act, which made several changes to the US patent system.

Knight has also held posts at the US Treasury Department and Department of Justice.

In September, he will join the Washington DC office of law firm McDermott, Will and Emery LLP as a partner in its IP litigation practise group.

Peter Sacripanti, co-chair of the firm said Knight’s arrival would aid its strategy of becoming the best IP law firm in the world.

“We are committed to providing the best possible counsel to our clients as they work to protect their valuable IP assets and succeed in today’s increasingly competitive marketplace,” he said.

The USPTO would not comment on the departure of Knight.

However, a spokesman told WIPR that William Covey, currently the deputy general counsel and director for office of enrolment and discipline, will take on the role of acting general counsel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Americas
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.